Bio-Techne at 50: CEO Kim Kelderman's Reflection on Five Decades of Platform Evolution & Strategic Priorities Ahead
About this episode
Kim Kelderman reflects on Bio-Techne's 50-year history and future growth strategies in an interview with Kyle Boucher.
Recorded on 03/03/26 TD Cowen life science & diagnostic tools analyst Kyle Boucher speaks with Bio-Techne CEO Kim Kelderman at TD Cowen's 46th Annual Health Care Conference to discuss Bio-Techne's 50-year anniversary, innovation and portfolio evolution, and growth pillars ahead. Since 1976 Bio-Techne has offered a wide range of critical reagents, assays, and analytical tools for customers in diagnostic, pharma, biotech, and academic settings, and has created one of the most consumables-focused portfolios in life science tools. CEO Kelderman reflects on Bio-Techne's 50-year history, including the last 10 years where the portfolio has grown through several inorganic acquisitions addressing multiple high-growth verticals that have laid the foundation for the next leg of growth.
More episodes of TD Cowen Insights
- Wellbeing, Longevity & Optimizing Healthspan With Mt. Sinai
- The New Budget Is Here! The New Budget Is Here!
- What's Happening With Alternative Investments?
- Saks Global's Next Act: Finance, Fashion, And Focus
- CEO Meeker & CFO Smith's Strategy To Build Rhythm Into The Leading Orphan Obesity Company
- FDA Engagement and the Evolving Psychedelic Therapy Landscape: A Conversation with Compass Pathways CEO Kabir Nath
Explore listener stats, chart rankings, contacts and more on the TD Cowen Insights podcast page.